#161683

Fibroblast specific Spag17 knockout mouse

Cat. #161683

Fibroblast specific Spag17 knockout mouse

Cat. #: 161683

Disease: Fibrocystic disease; Systemic sclerosis

Model: Knock-out

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Maria E Teves Ph.D., Jerome F Strauss III M.D Ph.D., and John Varga M.D.

Institute: Virginia Commonwealth University

Primary Citation: Sapao et al. J Invest Dermatol. 143(2):284-293 PMID: 36116512

Tool Details
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Tool name: Fibroblast specific Spag17 knockout mouse
  • Research fields: Systemic sclerosis and fibrosis
  • Disease: Fibrocystic disease; Systemic sclerosis
  • Model: Knock-out
  • Crispr: No
  • Description: This is a fibroblast specific, Tamoxifen inducible knockout mouse model for the deletion of the Spag17 gene. Reserachers identified the Spag17 gene as one differentially regulated in fibrotic diseases and created a mouse model was created with inducible fibroblast specific Spag17 knockout. Knockout Spag17 mice show significant fibrosis in skin, heart, lungs, kidneys, and skeletal muscle between 4-6 months of age. These mice have greater collagen deposition, enhanced fibroblast to myofibro...
  • Phenotype: Multi-organ fibrosis

References

  • Sapao et al. J Invest Dermatol. 143(2):284-293 PMID: 36116512